Changes may be coming for Medicare in 2027. New reports point to significant benefit reductions for some Medicare Advantage programs, including higher specialist copays and reductions or eliminations of programs that help pay Part B premiums. As more Americans face these changes, it’s more important than ever to know the options that are available to them.
Rising Cost of Prescription Drugs and More
While there are several issues contributing to the rising copays and significant benefit reductions, one major area of concern is the increasing cost of prescription drugs. The Inflation Reduction Act introduced an annual out-of-pocket limit for Medicare Part D. That limit was $2,000 in 2025 and increased to $2,100 in 2026, with future amounts scheduled to be indexed. Estimates show that more than one in five Part D beneficiaries reached the catastrophic spending level in 2025. Cancer and diabetes medications accounted for significant increases in spending, while spending on GLP-1 medications also grew.
As a new year looms, beneficiaries could face higher premiums, copayments and deductibles beginning in 2027. Medicare Advantage may see some changes as well. Insurance brokers have reported that some organizations are considering reducing certain supplemental benefits in 2027. These potential changes include smaller dental benefits, higher specialist copayments and adjustments to prescription-drug costs. Some plans that currently help cover Medicare Part B premiums may also reduce or eliminate that assistance.
Unintended Consequences of the Inflation Reduction Act
The Inflation Reduction Act, a landmark bill signed into law by President Biden in 2022, has been met with both praise and criticism since its inception. While the law was intended to empower Medicare to negotiate prices for certain high-cost prescription drugs, t researchers have raised concerns that some provisions could create financial and operational challenges for pharmacies.
As explained by a team of researchers with the National Library of Medicine,
Implementing MFP (Maximum Fair Price) for beneficiaries likely creates recurrent cash flow challenges for all pharmacies because of delayed DPNP (Drug Price Negotiation Program) reimbursement. Pharmacies may either buy DPNP drugs at MFP for Medicare patients or buy at list price and later claim the difference between acquisition cost and MFP from manufacturers. Pharmacies choosing the former approach would likely have to track the inventory separately for DPNP drugs, increasing their administrative burden.
Better Options are Available
As more Americans aging into Medicare face concerns about rising costs, it is important to remember that other options are available. At America’s HealthShare, we are committed to helping Americans achieve more affordable healthcare, regardless of age. Our COMPANION program is designed for Americans age 65+ enrolled in Medicare Parts A & B, helping share eligible out-of-pocket healthcare costs after Medicare processes your care.
For many Medicare Part B services, beneficiaries are responsible for 20% of the Medicare-approved amount after meeting the Part B deductible. We believe there is another option for managing these out-of-pocket expenses. Through COMPANION, eligible healthcare costs can be shared by the America’s HealthShare community.
Our Commitment to Affordable Healthcare
At America’s HealthShare, we are committed to providing our members and their families with affordable healthcare. We believe that senior citizens should not have to choose between accessing quality, necessary medical care and covering essential household expenses.
For more information about how you can join the America’s HealthShare community, please check pricing online or give our Member Care team a call today at (580) AMERI-HS.
